Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

Company Overview

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.30 to $7.17
• 52-Week Range: N/A
• Volume: 137,800 shs
• Average Volume: 103,866 shs
• Market Capitalization: $2.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Eiger BioPharmaceuticals Stock Analysis - MarketRank™

Eiger BioPharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Eiger BioPharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for EIGR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eiger BioPharmaceuticals does not currently pay a dividend.

Dividend Growth

Eiger BioPharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.65

Short Interest

There is no current short interest data available for EIGR.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for EIGR on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eiger BioPharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.22% of the stock of Eiger BioPharmaceuticals is held by insiders.

Percentage Held by Institutions

62.46% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EIGR Stock Analysis - Frequently Asked Questions

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%.

When did Eiger BioPharmaceuticals' stock split?

Eiger BioPharmaceuticals shares reverse split before market open on Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 1/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EIGR
• CUSIP: N/A
• CIK: 1305253
• Web: www.eigerbio.com
• Phone: (650) 272-6138
• Fax: 650-618-1621
• Employees: 56
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($59.1592)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-96,780,000.00
• Net Margins: -590.80%
• Pretax Margin: -590.79%
• Return on Equity: -332.49%
• Return on Assets: -99.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.31
• Quick Ratio: 3.24

Sales & Book Value

• Annual Sales: $15.77 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.68 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,480,000
• Free Float: 1,419,000
• Market Cap: $2.55 million
• Optionable: Optionable
• Beta: 1.83